ANARI-AI
Anari AI , an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird , with participation from Acequia Capital , Serbian Entrepreneurs , and Eric Ries , author and founder of The Lean Startup . The new funding will be used to continue developing the platform and bring it to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/
Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development.
“AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger , co-founder and Partner at Earlybird. “Dedicated designs or flexible architectures are expensive, time-consuming and require hardware skills (in short: take lots of effort). Anari is a game changer in two ways: it removes the trade-off between performance and effort, and it makes AI-problem-specific chip solutions available instantaneously in the cloud. I am excited about this huge potential.”
The platform is built on a unique Python-based programming framework—developed by Anari for chip design—that opens up new possibilities for hardware engineers and turns software engineers into hardware designers. The first configurable AI cloud chip from Anari is Thor X, which delivers 100x more efficient processing of 3D Point Cloud/Graph data structures compared to a high-end GPU.
Anari’s team consists of Ph.D. researchers, machine learning experts, and senior software engineers. The team is led by Jovan Stojanovic (co-founder and CEO), Stefan Sredojevic (co-founder and COO), and Bogdan Vukobratovic (co-founder and Head of R&D). Jovan is the founder of the Wonderland AI community that includes more than 30,000 AI experts and enthusiasts from all over the world. The yearly Wonderland AI Summit gathers C-level speakers and attendees from the world’s leading AI companies like NVIDIA, Airbus, HP, IBM, Mercedes, etc.
“You no longer have to tune your model to the computing infrastructure that’s available and designed for broad and generic use cases,” said Sasha Ostojic , ex-VP at NVIDIA, ex-SVP at Cruise Automation, Advisor at Samsung Electronics and Zoox, and Operating Partner at Playground Global.“ Anari's cloud chip technology is the future of cloud computing.”
Roland Manger and Sasha Ostojic will be joining Anari's Board of Directors. Advisors to the company include Christoph Auer-Welsbach (former Partner at IBM Ventures, Founder of CITY AI, and CEO of Kaizo) and Dejan Markovic (co-founder of Flex Logix and Professor at UCLA).
“With AI model complexity doubling every three and a half months, the current way of building the AI infrastructure is not sustainable,” said Jovan Stojanovic, co-founder and CEO of Anari AI. “We believe that every company deserves to have a personalized chip for their AI in just one click. We’re supporting the rapid progress of AI in ways that haven’t been possible until now. With experienced investors like Earlybird on our side, we’re ready to rebuild the AI hardware industry from scratch.”
About Anari AI
Anari AI is rebuilding the AI hardware industry from scratch by delivering a new way of designing and using AI chips through programming in the cloud. The Anari platform for cloud chips can be used by companies across industries such as gaming, automotive and biotechnology to personalize their AI infrastructure with just one click. The company is based in Serbia and has an office in San Francisco. The global team includes advisors with experience from NVIDIA, CERN, IBM, UC Berkeley, and UCLA.
For more information, visit www.anari.ai .
About Earlybird VC
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on digital technologies in Eastern and Western Europe as well as health technologies. Among them, the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. With EUR 1.5 billion under management, seven IPOs and 30 trade sales, Earlybird is one of the most successful venture capital firms in Europe. Discover more at www.earlybird.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005700/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom